Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
Public ClinicalTrials.gov record NCT03009201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed by surgery (advanced). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and doxorubicin hydrochloride may work better in treating patients with soft tissue sarcoma.
Study identification
- NCT ID
- NCT03009201
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 16 participants
Conditions and interventions
Conditions
- Advanced Soft Tissue Sarcoma
- Locally Advanced Angiosarcoma
- Locally Advanced Leiomyosarcoma
- Locally Advanced Liposarcoma
- Locally Advanced Malignant Peripheral Nerve Sheath Tumor
- Locally Advanced Myxofibrosarcoma
- Locally Advanced Undifferentiated Pleomorphic Sarcoma
- Metastatic Angiosarcoma
- Metastatic Epithelioid Sarcoma
- Metastatic Fibrosarcoma
- Metastatic Liposarcoma
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- Metastatic Myxofibrosarcoma
- Metastatic Soft Tissue Sarcoma
- Metastatic Synovial Sarcoma
- Metastatic Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma
- Pleomorphic Rhabdomyosarcoma
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7
- Undifferentiated (Embryonal) Sarcoma
- Unresectable Leiomyosarcoma
- Unresectable Liposarcoma
- Unresectable Malignant Peripheral Nerve Sheath Tumor
- Unresectable Soft Tissue Sarcoma
- Unresectable Synovial Sarcoma
- Unresectable Undifferentiated Pleomorphic Sarcoma
Interventions
- Doxorubicin Hydrochloride Drug
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Ribociclib Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 9, 2017
- Primary completion
- Oct 7, 2019
- Completion
- Jun 29, 2023
- Last update posted
- Aug 15, 2023
2017 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| OHSU Knight Cancer Institute | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03009201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2023 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03009201 live on ClinicalTrials.gov.